Healthcare - Press Releases

Marking four decades of innovation, Systech delivers a single platform to CDMOs that eliminates multi-vendor headaches and delivers visibility-from the packaging line to customer.

The industry veteran brings over 25 years of healthcare marketing expertise in accelerating growth and value for leading pharmaceutical brands

ABBOTT PARK, Ill., April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its VoltCE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt PFA System for the treatment of atrial fibrillation (AFib). The data also highlights the excellent safety profile of the Volt PFA System alongside the system's ability to achieve results with fewer therapy applications (just 4.7 applications per vein on average) than on-market competitive PFA systems.

GALWAY, Ireland and SAN DIEGO, April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9 combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal.

PISCATAWAY, N.J., April 26, 2025 /PRNewswire/ --Bestzyme is pleased to announce a flagship product Mellia Brazzein, has officially received the "No Questions" letter from the U.S. Food and Drug Administration (FDA) regarding its GRAS (Generally Recognized as Safe) status. The GRAS designation recognizes it as general-purpose sweetener for a wide range of applications in the food and beverage industry.

CHENGDU, Chine, 27 avril 2025 /PRNewswire/ -- Keymed BiosciencesInc. (HKEX: 02162) (Keymed ou la socit) a rcemment annonc que le CM518D1, un conjugu anticorps-mdicament (ADC) ciblant la CDH17 et mis au point par Keymed, a t autoris comme nouveau mdicament de recherche par le Centre d'valuation des mdicaments de l'Administration nationale des produits mdicaux et fait actuellement l'objet d'essais cliniques de phasesI/II en Chine pour le traitement de tumeurs solides. Cette tape marque une nouvelle avance dans le dveloppement des mdicamentsADC de Keymed, qui renforce ainsi son pipeline thrapeutique innovant dans le domaine de l'oncologie.

CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) (Keymed" oder das Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein von Keymed entwickeltes Antikrper-Wirkstoff-Konjugat (ADC), das auf CDH17 abzielt, vom Center for Drug Evaluation (CDE) der National Medical Products Administration (NMPA) die Zulassung fr ein neues Prfprparat (IND) erhalten hat und derzeit in China in klinischen Studien der Phase I/II zur Behandlung von soliden Tumoren getestet wird. Dieser Meilenstein markiert einen weiteren Durchbruch in Keymeds ADC Medikamentenentwicklung und strkt die innovative therapeutische Pipeline in der Onkologie.

CHENGDU, China, 27 de abril de 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" o la "compaa") anunci recientemente que CM518D1, un conjugado anticuerpo-frmaco (ADC) dirigido a CDH17 desarrollado por Keymed, recibi la aprobacin como Nuevo Medicamento en Investigacin (IND) del Centro de Evaluacin de Medicamentos (CDE) de la Administracin Nacional de Productos Mdicos (NMPA), y actualmente se encuentra en ensayos clnicos de Fase I/II en China para el tratamiento de tumores slidos. Este hito marca un nuevo avance en el desarrollo de frmacos ADC de Keymed, fortaleciendo an ms su innovadora cartera de productos teraputicos en oncologa.

SAN DIEGO, April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from theAVEIR Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area.CSP is a novel pacing approach that targets the LBB area by enabling pacing that mimics the heart's natural electrical rhythm.

More than 3,100 athletes swim, bike and run through downtown St. Petersburg as Dubrick wins second year in a row

CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integratedsolutionsfrom "Idea to IND" (I to ITM), today announcedthat its partner, Pfizer, has presented preclinical data onPF-08052666 (HBM9033; SGN-MesoC2), afirst-in-class topoisomerase 1 inhibitor (TOP1i)-based antibody-drug conjugate (ADC) targeting mesothelin (MSLN), at the AACR Annual Meeting 2025. This ADC was originally developed using Nona Biosciences' proprietary Harbour Miceand integrated ADC platforms. Pfizer acquired its global clinical development and commercialization rights on December 14, 2023.

SAN FRANCISCO and SUZHOU, China, April 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR meeting will take place April 25-30, 2025, in Chicago, Illinois.

SUZHOU, China, April 27, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster presentation at American Association for Cancer Research ("AACR") annual meeting.

SHANGHAI, April 27, 2025 /PRNewswire/ --Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors.

- OMRON Healthcare dona 4.000 monitores de presin arterial y avanza en la deteccin de fibrilacin auricular con tecnologa Intellisense AFib basada en IA

-Intellisense AFib-Technologie erkennt bei jeder Messung mgliches Vorhofflimmern; der 17. Mai ist Welt-Blutdrucktag im, dem Monat der Blutdruckmessung -May Measurement Month -

OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial was closed for recruitment at the end of 2023 and patients are currently in long-term follow-up.

OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update,Oncoinvent invites for a Live streamed of quarterly presentation in English on Wednesday 30thof April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.

SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stagein vivogene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT06458010), and the data has been published on medRxiv. YOLT-101 is an investigationalin vivobase editing therapy for the treatment of heterozygous familial hypercholesterolemia (HeFH). Clinical data demonstrate that YOLT-101 can safely and effectively reduce low-density lipoprotein cholesterol (LDL-C) levels in HeFH patients with a single administration. As a next-generation gene-editing therapy, YOLT-101 represents a breakthrough in lipid-lowering treatment - moving beyond daily pills and regular injections, and opening a new era of "one-time treatment for lifelong LDL-C reduction."

PAPHOS, Cyprus, April 28, 2025 /PRNewswire/ -- ILIKOS Consulting Group, a leader in commercial strategy, BD and corporate development solutions for Contract Research Organizations (CROs) and life-science companies proudly announces the launch of its new subsidiary in Greece. This strategic move underscores the company's commitment to expanding its international footprint and enhancing its portfolio of business solutions.

FUKUOKA, Japon, 28 avril 2025 /PRNewswire/ -- EditForce, Inc. (Sige social: Fukuoka, Japon) a le plaisir d'annoncer qu'un article de recherche sur les rsultats d'une tude conjointe avec le groupe de recherche dirig par le professeur Masayuki Nakamori du dpartement de neurologie de l'cole suprieure de mdecine de l'Universit de Yamaguchi, et le professeur Hideki Mochizuki du dpartement de neurologie de l'cole suprieure de mdecine de l'Universit d'Osaka, a t publi dans Science Translational Medicine le 16 avril 2025 (heure avance de l'Est).

STOCKHOLM, April 28, 2025 /PRNewswire/ -- Bioservo is excited to unveil the latest innovation in grip-strengthening technology, the New Carbonhand glove. This advanced glove features several enhancements and is designed to support different types of grips to make everyday tasks easier and more accessible. This also means that more people can benefit from Carbonhand.

LUXEMBURG, 24. April 2025 /PRNewswire/ -- Die Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), ein fhrender Innovator im Bereich Sport- und Gesundheitstechnologie, der fortschrittliche tragbare AIoT-Lsungen anbietet, die die berwachung der sportlichen Leistung nahtlos mit Echtzeit-Gesundheitsdaten verbinden, freut sich, Hubertus Bert" Hoyt als neuesten Berater des Vorstands bekannt zu geben.

LUXEMBOURG, April 23, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health tech, delivering advanced wearable AIoT solutions that seamlessly merge athletic performance monitoring with real-time health insights, is pleased to announce Hubertus "Bert" Hoyt as its newest Board Advisor.

- Un gran avance en la monitorizacin de la ciruga cerebral: Protegiendo vidas con la tecnologa de imagen trmica de Raytron